Dr. Paul H. Sugarbaker
Executive Summary
Dr. Paul H. Sugarbaker revolutionized the treatment of peritoneal mesothelioma—the form affecting the abdominal lining—by developing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC).[1] His innovation, known as the Sugarbaker procedure, transformed a uniformly fatal diagnosis into one where long-term survival became possible, with some patients living more than seven years.[2] The procedure involves complete visible removal of peritoneal tumors followed by 90 minutes of heated chemotherapy solution (42-43°C) circulated through the abdomen, allowing regional treatment without systemic toxicity. Through decades of research, Dr. Sugarbaker developed three distinct treatment protocols that became the international standard of care, endorsed by the Peritoneal Surface Oncology Group International (PSOGI).[3]
Peritoneal mesothelioma accounts for approximately 10-20% of all mesothelioma cases and develops in the peritoneum, the membrane lining the abdominal cavity. Before Dr. Sugarbaker's innovations, patients with this diagnosis faced a median survival of less than one year with conventional chemotherapy alone. His recognition that heated chemotherapy could penetrate tumor tissue more effectively than systemic treatment led to the development of HIPEC protocols that have since been adopted by specialized cancer centers worldwide.[4]
The three treatment protocols Dr. Sugarbaker developed represent increasingly aggressive approaches based on disease extent and patient condition. Protocol 1 combines cytoreductive surgery with immediate HIPEC; Protocol 2 adds early postoperative intraperitoneal chemotherapy (EPIC) for five days following surgery; Protocol 3 further adds long-term normothermic intraperitoneal chemotherapy (NIPEC) administered through an implanted abdominal port. These graduated approaches allow treatment to be tailored to individual patient needs while maximizing the chance for long-term disease control.[5]
Key Facts
| Key Facts: Dr. Paul H. Sugarbaker's Contributions |
|---|
|
Who Is Dr. Paul H. Sugarbaker?
Dr. Paul H. Sugarbaker is a surgical oncologist who dedicated his career to developing treatments for cancers affecting the peritoneum—the lining of the abdominal cavity.[6] While sharing a surname with Dr. David Sugarbaker (the thoracic surgeon who pioneered extrapleural pneumonectomy for pleural mesothelioma), the two physicians are not related and worked independently on different forms of the disease.
Dr. Paul H. Sugarbaker's focus on peritoneal surface malignancies led him to recognize that traditional systemic chemotherapy was largely ineffective for cancers confined to the abdominal cavity. The peritoneum's unique anatomy—a closed space where tumors spread along surfaces rather than through the bloodstream—required a completely different treatment approach.[7]
| "Dr. Paul H. Sugarbaker's work gave peritoneal mesothelioma patients something that didn't exist before: a chance at long-term survival. Before HIPEC, this diagnosis was essentially a death sentence. Now we can tell patients about a treatment that has helped some people live seven years or more." |
| — Paul Danziger, Founding Partner, Danziger & De Llano |
What Is the Sugarbaker Procedure?
The Sugarbaker procedure combines two treatment modalities that work synergistically to treat peritoneal mesothelioma:[8]
Cytoreductive Surgery (CRS)
The first component involves surgically removing all visible tumor from the abdominal cavity. This includes:
- Stripping affected peritoneal surfaces
- Removing involved organs or portions of organs when necessary
- Eliminating all macroscopic (visible) disease
The goal is complete cytoreduction—leaving no visible cancer behind. The completeness of cytoreduction is the single most important factor determining patient outcomes.[9]
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Immediately following cytoreductive surgery, while the patient is still in the operating room, heated chemotherapy solution is circulated throughout the abdominal cavity for 90 minutes.
| HIPEC Parameter | Specification |
|---|---|
| Temperature | 42-43°C (107-109°F) |
| Duration | 90 minutes |
| Delivery | Circulated through open abdomen |
| Chemotherapy Agents | Varies by protocol (commonly mitomycin C, cisplatin) |
| ✅ Why Heat Matters: The elevated temperature of HIPEC serves multiple purposes. Heat directly kills cancer cells, increases chemotherapy penetration into remaining microscopic disease, and enhances drug effectiveness. The regional delivery allows higher drug concentrations than would be tolerable with IV chemotherapy. |
What Survival Outcomes Has the Sugarbaker Procedure Achieved?
Dr. Sugarbaker's research demonstrated that patients could achieve survival ranging from 2.5 years at the low end to more than 7 years at the high end—a dramatic improvement over the historical prognosis of less than one year for peritoneal mesothelioma.[10]
| Factor | Impact on Survival |
|---|---|
| Completeness of Cytoreduction | Most important factor - complete visible removal essential |
| Histologic Subtype | Epithelioid tumors respond better than sarcomatoid |
| Tumor Volume | Lower volume disease has better outcomes |
| Lymph Node Status | Node-negative patients do better |
| Treatment Center Experience | High-volume centers achieve better results |
| ℹ️ Why Peritoneal Has Better Prognosis: Peritoneal mesothelioma generally has better survival outcomes than pleural mesothelioma. The abdominal cavity's anatomy allows for more complete surgical removal, and the disease tends to remain localized longer before spreading to distant sites. |
Where Can Patients Access HIPEC Treatment Today?
The Sugarbaker procedure is now offered at specialized cancer centers throughout the United States.[11] Because of its complexity, HIPEC should only be performed at high-volume centers with experienced surgical teams.
Leading HIPEC Centers Include:
- University of Chicago Medicine
- Memorial Sloan Kettering Cancer Center
- MD Anderson Cancer Center
- Washington Cancer Institute
- Wake Forest Baptist Medical Center
| ⚠️ Center Selection Matters: Outcomes for HIPEC are significantly better at experienced centers. Patients should seek evaluation at institutions that perform the procedure regularly and have published survival data for peritoneal mesothelioma patients. |
| "When we help clients with peritoneal mesothelioma, one of our first discussions is about HIPEC and which centers have the most experience. Dr. Sugarbaker's procedure offers real hope, but getting the best outcomes means getting to the right treatment center. We help families navigate these critical decisions." |
| — David Foster, Client Advocate, Danziger & De Llano |
What Is Dr. Paul H. Sugarbaker's Legacy?
Dr. Paul H. Sugarbaker's contributions fundamentally changed the prognosis for peritoneal mesothelioma patients:[12]
Before the Sugarbaker Procedure:
- Peritoneal mesothelioma was uniformly fatal
- Median survival was less than one year
- No standard treatment existed
- Patients received only palliative care
After the Sugarbaker Procedure:
- Long-term survival became possible (5-7+ years)
- International treatment standards were established
- Specialized centers developed worldwide
- Patients have a fighting chance at extended life
His work demonstrates how a single researcher's dedication can transform outcomes for patients with rare diseases.[13]
Get Help Today
If you or a loved one has been diagnosed with peritoneal mesothelioma, accessing specialized treatment—including the HIPEC procedure Dr. Sugarbaker developed—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your asbestos exposure.[14]
The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.
📞 Call (866) 222-9990 or request a free case review online.
See Also
- History of Mesothelioma Research
- Dr. David Sugarbaker (Pleural Mesothelioma Surgeon - Not Related)
- Peritoneal Mesothelioma
- Treatment Options
- Mesothelioma Treatment Centers
References
- ↑ Peritoneal Mesothelioma Treatment, National Cancer Institute
- ↑ PubMed: Sugarbaker Peritoneal Mesothelioma, National Library of Medicine
- ↑ HIPEC Definition, NCI Dictionary of Cancer Terms
- ↑ Cancer Stat Facts: Mesothelioma, NCI SEER Program
- ↑ Peritoneal Mesothelioma Clinical Trials, ClinicalTrials.gov
- ↑ Mesothelioma, National Cancer Institute
- ↑ Chemotherapy to Treat Cancer, National Cancer Institute
- ↑ Surgery to Treat Cancer, National Cancer Institute
- ↑ Cytoreductive Surgery Definition, NCI Dictionary
- ↑ Cancer Stat Facts: Mesothelioma, NCI SEER
- ↑ NCI-Designated Cancer Centers, National Cancer Institute
- ↑ VA Asbestos Exposure, U.S. Department of Veterans Affairs
- ↑ Asbestos, Occupational Safety and Health Administration
- ↑ What's Your Mesothelioma Case Worth?, Danziger & De Llano